NRx Pharmaceuticals has the potential to build a pipeline of novel CNS-focused therapeutics. We believe that our leadership in the science of the N-methyl-D-asparate (NMDA) receptor, and how it may affect various disorders marked by depression, strongly positions us to pursue additional indications.

Our initial focus is on Bipolar Depression in patients with Acute/Subacute Suicidal Ideation/Behavior (ASIB/SSIB), and PTSD. Thereafter the company plans to expand into Major Depressive Disorder (MDD) in patients with ASIB and chronic depression.